SecBot SecBot
PRESS-RELEASE ·Filed Mar 10, 2026

VTVT

vTv Therapeutics Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The $20 million non-dilutive funding and strong cash position reduce near-term financing risk and support execution through the CATT1 topline readout. Traders should monitor enrollment completion in Q3 2026 and any updates on trial progress as key catalysts. However, the widening losses and lack of revenue may pressure sentiment if clinical milestones are delayed.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$35.10
T+0 close · Mar 10, 2026 · via day close
Latest settled
−6.15%
T+60 · $32.94
Vs SPY
−17.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $35.10entry
  2. T+1 · 8mo ago −3.96%α −2.48% · $33.71
  3. T+5 · 8mo ago +3.42%α +5.61% · $36.30
  4. T+20 · 7mo ago +6.27%α +5.74% · $37.30
  5. T+60 · 6mo ago −6.15%α −17.68% · $32.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

vTv Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a significant cash increase to $88.9 million from an $80 million financing and a $20 million upfront payment from Newsoara under an amended licensing deal. The company expects to complete enrollment in its Phase 3 CATT1 trial for cadisegliatin in Q3 2026, with a funding runway extending beyond the topline readout. However, net losses widened year-over-year due to higher R&D and G&A expenses.

Key Financial Metrics

Revenue
$0.00
-100.0% YoY
EPS
$-3.20
Deal Value
$20.0M

Key Facts

  • Received $20.0 million upfront from Newsoara in February 2026 under an amended licensing agreement for global rights to PDE4 inhibitor HPP737.
  • Cash position was $88.9 million as of December 31, 2025, up from $36.7 million a year prior, driven by $80 million private placement and licensing proceeds.
  • Net loss for Q4 2025 was $7.1 million vs. $3.6 million in Q4 2024; full-year 2025 net loss was $27.0 million vs. $18.5 million in 2024.
  • R&D expenses increased to $17.9 million in 2025 from $11.5 million in 2024, primarily due to cadisegliatin clinical trials.
  • Enrollment in the Phase 3 CATT1 trial is expected to complete in Q3 2026, with topline data to follow.
  • No revenue was generated in 2025, compared to $1.0 million in 2024.

Financial Impact

Cash increased by $52.2 million YoY; $20 million non-dilutive licensing inflow in 2026 strengthens near-term liquidity. However, operating losses expanded significantly, with full-year net loss up 46% YoY.

cashnet_lossr_and_d_expenseg_and_a_expense

Risk Factors

  • Clinical trial delays could push back topline data and increase cash burn.
  • Cadisegliatin may fail to demonstrate efficacy or safety in Phase 3, leading to a significant stock decline.
  • Future warrant liability fluctuations could create additional non-cash volatility in earnings.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3253292

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 10, 2026